Americas · Regional markets · Financial Post

Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma

Published by Financial Post · Canada 1 h ago

SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven…

Read the full article on Financial Post Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (financialpost.com)

Also worth reading

BNN Bloomberg

OpenAI resumes frontier AI training after security overhaul, discloses flaw in widely used software

El Cronista

Dólar hoy: a cuánto cotiza el oficial en los bancos de la City hoy sábado 24 de octubre

La República

Remesas suman 28 meses consecutivos arriba del techo de US$1.000 millones

Ámbito

Belgrano Cargas y zona cálida, dos frentes que tensionan el vínculo de Nación con los gobernadores norteños

Bloomberg Línea

SpaceX afronta dificultades en las negociaciones por su deuda de US$40.000 millones para IA

Gestión